Tenofovir disoproxil fumarate (TDF) has been approved for chronic hepatitis B treatment, and favorable susceptibility of hepatitis B virus (HBV) has been indicated. However, differences in TDF susceptibility among HBV genotypes and drug-resistant strains are unclear. In this study, TDF susceptibilities between genotypes A and C were evaluated in vitro and in vivo using several drug-resistant HBV clones.

Authors: Eisuke Murakami, Masataka Tsuge, Nobuhiko Hiraga, Hiromi Kan, Takuro Uchida, Keiichi Masaki, Takashi Nakahara, Atsushi Ono, Daiki Miki, Tomokazu Kawaoka, Hiromi Abe, Michio Imamura, Hiroshi Aikata, Hidenori Ochi, C Nelson Hayes, Tomoyuki Akita, Junko Tanaka, Kazuaki Chayama

Read publication

Back to Resources